Marksans Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	-	6,341	4,958	4,033	3,824	2,064
Short-Term Investments	-	3,567	2,094	2,710	3,328	1,399
Trading Asset Securities	-	-	7.42	269.94	5.4	4.35
Cash & Short-Term Investments	9,909	9,909	7,060	7,013	7,158	3,467
Cash Growth	40.36%	40.36%	0.67%	-2.03%	106.47%	63.19%
Accounts Receivable	-	6,446	5,400	4,532	4,168	3,948
Other Receivables	-	141.63	144.04	106.62	48.5	43.7
Receivables	-	6,587	5,544	4,638	4,217	3,991
Inventory	-	9,723	8,455	6,179	4,847	4,244
Prepaid Expenses	-	368.88	302.63	251.26	198.04	159.83
Other Current Assets	-	639.61	679.24	543.05	332.57	149.34
Total Current Assets	-	27,227	22,041	18,625	16,753	12,012
Property, Plant & Equipment	-	9,407	8,954	6,811	3,869	3,423
Long-Term Investments	-	0.1	0.1	1.68	-	-
Goodwill	-	452.56	409.28	394.99	384.89	300.25
Other Intangible Assets	-	1,168	727.32	647.62	707.97	585.69
Long-Term Deferred Tax Assets	-	129.65	-	-	-	38.57
Other Long-Term Assets	-	224.97	264.32	329.41	189.13	41.62
Total Assets	-	38,609	32,396	26,810	21,904	16,401

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Accounts Payable	-	3,369	3,057	2,683	2,306	2,001
Accrued Expenses	-	600.89	644.31	442.56	220.96	131.01
Short-Term Debt	-	295.91	230.85	290.91	415.88	362.92
Current Portion of Long-Term Debt	-	-	-	-	-	50
Current Portion of Leases	-	436.58	354.92	249.51	156.68	280.52
Current Income Taxes Payable	-	415.83	299.41	199.08	252.78	173.27
Other Current Liabilities	-	152.6	186.91	33.66	57.59	563.67
Total Current Liabilities	-	5,271	4,773	3,898	3,410	3,562
Long-Term Leases	-	2,701	2,633	1,900	656.89	414.34
Pension & Post-Retirement Benefits	-	47.12	49.47	38.96	23.22	15.73
Long-Term Deferred Tax Liabilities	-	50.87	36.62	106.2	153.86	176.21
Other Long-Term Liabilities	-	12.03	9.73	6.63	9.3	2.83
Total Liabilities	-	8,082	7,503	5,950	4,253	4,171

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Common Stock	-	453.16	453.16	453.16	453.16	409.31
Additional Paid-In Capital	-	5,045	5,045	5,045	5,045	1,732
Retained Earnings	-	21,184	17,358	13,827	10,913	8,230
Comprehensive Income & Other	-	3,549	1,813	1,326	1,040	1,651
Total Common Equity	30,232	30,232	24,669	20,651	17,452	12,023
Minority Interest	-	295.24	224.7	208.52	199.1	207.01
Shareholders' Equity	30,527	30,527	24,894	20,859	17,651	12,230
Total Liabilities & Equity	-	38,609	32,396	26,810	21,904	16,401

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Total Debt	3,434	3,434	3,219	2,441	1,229	1,108
Net Cash (Debt)	6,475	6,475	3,841	4,572	5,929	2,359
Net Cash Growth	68.59%	68.59%	-16.00%	-22.88%	151.30%	36.10%
Net Cash Per Share	14.28	14.29	8.48	10.09	14.27	5.76
Filing Date Shares Outstanding	452.93	453.16	453.16	453.16	453.16	409.31
Total Common Shares Outstanding	452.93	453.16	453.16	453.16	453.16	409.31
Working Capital	-	21,957	17,268	14,726	13,343	8,450
Book Value Per Share	66.71	66.71	54.44	45.57	38.51	29.37
Tangible Book Value	28,611	28,611	23,533	19,608	16,359	11,137
Tangible Book Value Per Share	63.14	63.14	51.93	43.27	36.10	27.21
Land	-	5.82	5.31	5.18	5.1	4.67
Buildings	-	3,121	2,815	2,287	1,633	1,511
Machinery	-	6,506	5,701	4,445	3,355	3,038
Construction In Progress	-	147.82	90	53.81	72.46	6.95
Leasehold Improvements	-	142.64	116.61	105.64	-	-